WallStSmart

Advanced Biomed Inc. Common Stock (ADVB)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ADVB leads profitability with a 0.0% profit margin vs -9.1%. ADVB earns a higher WallStSmart Score of 36/100 (F).

ADVB

Hold

36

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 7.8
Piotroski: 4/9

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.8
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADVB3 strengths · Avg: 10.0/10
P/E RatioValuation
1.1x10/10

Attractively priced relative to earnings

Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

NTRA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
38.8%10/10

Revenue surging 38.8% year-over-year

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Areas to Watch

ADVB4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.18M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

NTRA4 concerns · Avg: 3.3/10
Price/BookValuation
17.3x4/10

Trading at 17.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-12.8%2/10

ROE of -12.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ADVB

The strongest argument for ADVB centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.

Bear Case : ADVB

The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

ADVB profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA is growing revenue faster at 38.8% — sustainability is the question.

NTRA generates stronger free cash flow (18M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ADVB scores higher overall (36/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Biomed Inc. Common Stock

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?